98%
921
2 minutes
20
There is a little evidence on efficacy of pharmacy-based interventions on clinical outcomes of type 2 diabetes mellitus (T2DM) patients in Pakistan. To appraise the impact of pharmacist-led self-care education on glycemic control, self-care practices and disease knowledge of T2DM patients with poor glycemic control (HbA1c ≥ 7%). In this 6-months, randomized controlled trial (RCT), = 75, T2DM patients seeking care at a diabetes clinic were randomized in to two groups. Intervention group ( = 38) received two face-to-face educational sessions (at enrollment and on week 12), whereas control group ( = 37) received usual care. Outcome measures such as glycemic control, self-care practices and disease knowledge were assessed at the time of enrollment and after 6-months in both groups. Thirty-three intervention and thirty-three participants from the control group completed the study. Mean glycated hemoglobin (% HbA1c) significantly reduced in the intervention group from 9.00 ± 1.43 to 8.09 ± 1.16 ( < .01). However, no significant change was observed in the control group (9.20 ± 1.24 to 8.93 ± .97; = .06). Cohen's d effect size of the intervention on HbA1c was .78. Percentage of participants achieving glycemic control (HbA1c < 7%) were significantly higher ( < .05) in the intervention group as compared to the control group (twenty-four vs. six), after 6 months of the trial. A significant ( < .01) improvement in mean scores for disease knowledge and self-care activities was also observed in the intervention group participants, whereas no significant improvements ( > .05) were observed in the control group. The study demonstrated an improvement in glycemic control, disease knowledge and self-care activities of T2DM patients who received pharmacist-led educational intervention. The study findings support clinical significance of integrating pharmacy-based interventions in diabetes management.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864215 | PMC |
http://dx.doi.org/10.3389/fphar.2022.754999 | DOI Listing |
Cell Mol Biol (Noisy-le-grand)
September 2025
M-DT1, Roquefort-les Pins, France.
To date, the closed-loop system represents the best commercialized management of type 1 diabetes. However, mealtimes still require carbohydrate estimation and are often associated with postprandial hyperglycemia which may contribute to poor metabolic control and long -term complications. A multicentre, prospective, non-interventional clinical trial was designed to determine the effectiveness of a novel algorithm to predict changes in blood glucose levels two hours after a usual meal.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
September 2025
Medical School, Laboratory of Genetics and Molecular Pathology, University Hassan II, Casablanca, Morocco.
In-stent restenosis remains a significant challenge in interventional cardiology despite technological advancements. This retrospective case-control study conducted at the University Hospital Center Ibn Rochd in Casablanca (2020-2023) examined risk factors associated with coronary in-stent restenosis in 68 patients equally distributed between restenosis and no-restenosis groups. Diabetes emerged as a powerful predictor of restenosis (RR=4.
View Article and Find Full Text PDFDiabetes Ther
September 2025
Department of Diabetes and Endocrinology, Guy's and St Thomas' NHS Trust, London, UK.
Introduction: This post hoc analysis of an A Toujeo Observational Study (ATOS) aims to evaluate the real-world effectiveness and safety of insulin glargine 300 U/ml (Gla-300) in high-risk subgroups of insulin-naïve people with type 2 diabetes (PwT2D) from multiple geographical regions (Asia, the Middle East, North Africa, Latin America, and Eastern Europe).
Methods: In these post hoc analyses of ATOS, a real-world, 12-month, prospective study included 4422 insulin-naïve adults (age ≥ 18 years) with type 2 diabetes (T2D) uncontrolled (HbA > 7% and ≤ 11%) on one or more oral antidiabetic drugs (OADs) who initiated Gla-300 treatment as per routine practice. Primary and secondary endpoints were studied according to renal impairment (RI) status (without or with) and age group (≥ 70 years).
Int J Vitam Nutr Res
August 2025
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Dhaka, 1000 Dhaka, Bangladesh.
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia and associated with severe complications, including cardiovascular diseases, neuropathy, nephropathy, and retinopathy. Although synthetic antidiabetic drugs are available, the side effects and limited long-term effectiveness of these medications highlight the urgent need for safer, more potent alternative therapies. L.
View Article and Find Full Text PDFInt J Vitam Nutr Res
August 2025
Department of Endocrinology, Affiliated Hospital of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, 210028 Nanjing, Jiangsu, China.
Background: Dietary interventions have exhibited promise in restoring microbial balance in chronic kidney disease. A low-protein calorie-restricted diet can reduce kidney injury in diabetic rodents. However, whether the renoprotective effects of this dietary intervention in murine diabetic kidney disease models are linked to gut microbiota modulation remains to be determined.
View Article and Find Full Text PDF